Clearside Biomedical, Inc. Aktie News

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S.

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a F...

Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector ® - - Strengthened Capital Position from Registered Direct Equity Offering and Recent SCS Microinjector License Agreement - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Manage...

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providi...